Why the study?
Does low-dose enalapril or irbesartan improve renal outcomes in experimental diabetic nephropathy?
Population
Sprague-Dawley rats with diabetes mellitus induced by 50 mg/kg streptozotocin
Comparison
Enalapril 2.5 mg/kg or Irbesartan 5 mg/kg… vs Patient control group and healthy control group
Design
Preclinical
Follow-up
6 weeks
Authors
Loading...
Does not support clinical use in diabetic nephropathy; hypothesis-generating for comparable RAS inhibitor renoprotection in experimental models.
Does low-dose enalapril or irbesartan improve renal outcomes in experimental diabetic nephropathy?
Low-dose enalapril and irbesartan provide comparable renal protective effects in an experimental model of diabetic nephropathy independent of blood pressure changes.
Yalçın et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: